Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

NCT00045526 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Recurrent Esophageal Cancer
Squamous Cell Carcinoma of the Esophagus
Stage III Esophageal Cancer
Stage IV Esophageal Cancer

Interventions

DRUG: erlotinib hydrochloride
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)